Drug firm Strides Arcolab today said it has received the nod from the US Food and Drug Administration (USFDA) to sell Vecuronium Bromide injections, a muscle relaxant, in the US market.
The approval is for injections containing 10 mg and 20 mg of Vecuronium Bromide per vial, the company said in a statement.
Vecuronium Bromide is used to provide muscle relaxation during surgery or mechanical ventilation and last year in the US, sales of the injection totalled $10 million as per IMS data, it added.
The medicine will be launched in the near future under the joint venture between Strides and Akorn Inc, called Akorn-Strides, it said.
Strides is currently developing and supplying 22 injectable products for the US market. The products will be marketed by Akorn Inc.
The latest approval from the USFDA is the eighth approval that the company has received from the US health regulator in 2010.
